Then, when he was 10, Sallas transitioned to a longboard and discovered a talent for stylishly maneuvering a 9-foot-plus board. And by the time he was 12, Sallas knew he wanted to dedicate his ...

Cute features in babies and animals are more than just amusing—they trigger powerful evolutionary responses that help our species’ survival. Moo Deng, the baby pygmy hippo that has become ...

Shares of Longboard Pharmaceuticals Inc. are surging more than 51% Monday, boosted by H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical company.

H. Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug pipeline for serious brain diseases. The Danish pharmaceutical company is offering ...

Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion ...

Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion, driven by the potential of bexicaserin. Bexicaserin shows promising seizure reduction ...

After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is scooping up the biotech for $2.5 billion. At the heart of the buyout is ...

Oct 14 (Reuters) - H Lundbeck A/S (HLUNb.CO), opens new tab has agreed to buy U.S.-based Longboard Pharmaceuticals (LBPH.O), opens new tab for $2.6 billion, marking the biggest deal ever by the ...

LONDON — The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals, which is developing treatments for neurological diseases, in a deal worth $2.6 billion.

Longboard is a clinical-stag Denmark-based H. Lundbeck A/S on Monday agreed to acquire Longboard Pharmaceuticals, Inc (NASDAQ:LBPH) for $60.00 per share in cash.

H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. The acquisition strengthens Lundbeck's pipeline with bexicaserin, a potential treatment for Dravet syndrome and other neurological ...